Phosphagen. Share Discussion Threads

[spaceparallax] 26/2/2007 13:38

Just had a glance through the horrendously formatted document in the RNS - I'm presuming that PSG are compelled to adopt that format because it seems to me that otherwise no one in their right mind would.

The one thing which I came away with was that there appears to be a reduction in loss per share cf last year.

[spaceparallax] 23/2/2007 09:54

Looks like we too can have shares at 12p and without all the currency hassle.

[hopeless698] 13/2/2007 17:37

What's happening out there! Price has dropped in last week or so.

[donaferentes] 07/2/2007 19:24

Interested to see which way the chart breaks after its run out of space to oscillate futher.

[lgw] 07/2/2007 13:09

Tom sold so many shares(companies) out of his portfolio last issue (feb 07) that he will have to replace them with something.

As for psg we are back to watching paint dry I guess.

[donaferentes] 05/2/2007 13:55

Well, Tom has to move the portfolio along when he can to make room for new shares - so I take his sell as nothing more than that really. Lack of action is a trader's problem, not an investor's!?!

[lgw] 05/2/2007 13:13

I think that the penny sleuth are tied up with Red Hot Penny Shares.
RHPS had recommended PSG to clients only to recommend selling due to lack of action in the share price.
I will put 2&2 together and guess that Tom bulford (RHPS) is looking again at putting out a buy rec on PSG but is wanting to raise the profile of Penny Sleuth by letting them get in there first.

[donaferentes] 24/1/2007 10:02

This ones a bit like FOGL. I'm totally convinced they will get there, but it could still be a couple of years away on all/any of their excellent phosphorylated products - insulin, morphine, vitE.

There is a case to sell up and come back later in plenty of time. But somehow I like having my small stake - it keeps me involved.

[spaceparallax] 24/1/2007 08:58

KKTJ,

Thanks, good plug once they eventually got there.

[suesean1] 23/1/2007 07:30

Up again in Aus, five days on the trot, giddyup.

[spaceparallax] 22/1/2007 15:20

Looking up.

[ladybird1] 18/1/2007 14:05

Indeed, Gaudeamus! You are right to note that the products are progressing & have not yet fallen at a fence.

As people are noting, however, still a long race ahead.

[donaferentes] 18/1/2007 12:18

ptolemy - nor in which countries, each one requiring differnt approvals.

labdybird - I could never imagine a major Swiss corporation disclosing commercial details to a mere shareholder!

However, this is fantastic news. The hardest part is not the science - it's bringing it to market commercially and succssfully. Soo many other embryonic compnaies with exciting new products fail at this stage. Nestle's experience and weight could not be better. I think we can trust them to make sure the timescale is not over-extended. Whether we can trust them to pay as much as the gear is properly worth may be another question, but we should be able to look forward to decent w/wide volume to compensate for the price.

This is what we're in it for. Another almost faultless quality step forward by the management. Let's rejoice.

[ladybird1] 18/1/2007 10:16

Nor I. Had there been agreement not to disclose, the sensible thing would be specifically to say so. The implication has to be as you suggest, that Nestle have used a strong negotiating position on a product that, while showing promise, if they turned it down is not so self evidently brilliant that a new sponsor could readily be found.

[worc0670] 18/1/2007 10:09

I expect the costs of the trials will be split as were the original pre-clinical trials for phospha-E. After this it'll certainly be Nestle bearing the costs wince all PSG can contribute is the ester-E product. This is the point of the agreement - that Nestle can produce and market a decent product.

I too had been looking forward to knowing the value of the fee however. Not stating this can only make people assume that it's not very much. On the pther hand, I can't see how it'd be undisclosable??.

[spaceparallax] 18/1/2007 09:29

Looks good to me too.

We all know that trials take time, but this could be a very significant step in the right direction.

[rambutan2] 18/1/2007 09:02

looks good to me - remember, this is a long game.

[ladybird1] 18/1/2007 08:35

Very well put.

Also gives no financial details of the option fee nor, perhaps more crucially, who will bear the costs of the development, ie. where the commercial risk will lie.

Disappointing, after the hype.

[ptolemy] 18/1/2007 08:05

Interesting but it omits to say that trials will take more than a year and the regulatory process is of unknown length.

[suesean1] 18/1/2007 07:17

Phosphagenics Statement re commecial discussions with Nestle


Melbourne, Australia: 18 January 2007 Nestlé Nutrition enters commercial discussions with Phosphagenics Key points: * Nestlé Nutrition has exercised its option to negotiate a commercial
agreement to use Phosphagenics' Phospha-E® as a nutritient in medical foods
for treating and preventing metabolic syndrome.
* The terms of the option agreement include the following.
a. The payment by Nestlé Nutrition of an option fee to Phosphagenics.
b. One or both parties will conduct human clinical trials to enable health
claims for the treatment and prevention of metabolic syndrome.
c. Nestlé Nutrition will launch a product for metabolic syndrome within 12
months of regulatory approval.
d. Phosphagenics will manufacture and sell Phospha-E® to Nestlé Nutrition.
e. Phosphagenics will grant Nestlé Nutrition a worldwide exclusive licence for
the use of Phospha-E® as a nutrient in foods for the treatment and
prevention of metabolic syndrome.
Phosphagenics Limited ("Phosphagenics") (ASX:POH) (AIM:PSG) announced today
further details of its option agreement with Nestlé Nutrition which grants the
Nestlé speciality nutrition business the right to negotiate, on an exclusive
worldwide basis, a commercial agreement to use Phosphagenics' Phospha-E®
product for the treatment and prevention of metabolic syndrome. These
announcements follow on from the successful completion of a series of full
dose-response pre-clinical studies on Phospha-E® previously announced to the
market in December, 2006.
Under the terms of the option agreement, Nestlé Nutrition will pay
Phosphagenics an option fee, and the parties will commence human clinical
trials with Phospha-E® to provide science-based evidence that Phospha-E® is
beneficial in the treatment and prevention of metabolic syndrome.
The option agreement requires Nestlé Nutrition to launch a product within 12
months of regulatory approval. Also, under the agreement, Phosphagenics will be
responsible for the manufacture and sales of Phospha-E® to Nestlé Nutrition.
Mr Harry Rosen, Managing Director of Phosphagenics said: "Phosphagenics is
delighted that our nutraceutical division has reached this stage of commercial
development for Phospha-E® with the speciality nutrition business of the
world's largest food company.""It is very exciting that we have been able to partner with, in my view, the
world's most progressive specialised nutrition company. Phosphagenics is
looking forward to working closely with Nestlé Nutrition to bring Phospha-E® to
market for this indication as quickly as possible."The final results of the two pre-clinical multi-dose response trials announced
to the market on 14 December 2006, confirmed that when given orally, Phospha-E®
significantly reduced many of the key biomarkers associated with metabolic
syndrome, inflammation and cardiovascular disease. Additionally, the most
appropriate dosage required to commence human clinical trials was also
determined.
In these trials, animals treated with varying doses of Phospha-E® were shown to
have statistically significant reductions in key parameters such as plaque
formation, aortic vascular dysfunction, cholesterol, triglycerides and LDL-C
(so-called bad cholesterol).

[sf5] 12/1/2007 19:46

Esteon - curiously CSS advised me not to bother with the PSG offer as there were rumours the business might be demerged into the nutri- and pharma- divisions. I wasn't paying too much attention so might have got mixed messages?

Admittedly not a large sample, but CSS's AIM listings haven't exactly covered themselves in glory.

Miras Imaging still hasn't got off the ground. Likewise NoNox.
SEV dropped from 65p to low 20's – now near 30p.
CBX dropped from 22.5p to 10p [where I topped up in a secondary offer] – now 15p.
GRNK [Ofex / Plus Markets] has almost halved but was suspended this week pending acquisition of a US coatings company [with fund raising].
RET / ETS all rather confusing but I'm showing a small profit.

IAM is the exception and has more than doubled from my entry at 62.5p to 145p. I'm not sure though that CSS handled the original flotation - I was originally offered this as convertible loan stock at 100p or thereabouts but declined.

Volumes tend to be very low in these stocks. There's little trading interest or news in an overcrowded AIM market making it so easy for the price to drift down. My conclusion is to study the prospectus, ask questions, but decline the initial offer unless it looks a real humdinger. There may well be an opportunity to drip feed in after a few months and the first trading updates. I suspect some of these companies are being brought [expensively] to market too early and would do better to stay private a few years longer and build up a decent trading record.

Just my thoughts, anyway
Simon